Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanogen licenses Canavan gene mutations:

This article was originally published in Clinica

Executive Summary

Nanogen's efforts to develop a panel of tests for the Ashkenazi Jewish population has received a boost. The San Diego, California firm has licensed three of the most common gene mutations associated with diagnosing Canavan disease, a deadly genetic disorder that primarily strikes infants of eastern and central European Jewish (Ashkenazi) descent. The non-exclusive licence agreement was formed with US firm Miami Children's Hospital Research Institute. Nanogen says that Canavan disease attacks an infant's brain and prevents normal development, eventually resulting in premature death. It adds that around 90% of the American Jewish population is of Ashkenazi descent, from which one in 40 is a carrier of the Canavan gene.

You may also be interested in...



Majority Of Spanish OTC Firms Investing Heavily In Digital

A recent ANEFP survey shows that the majority of Spanish OTC firms consider their digital strategies to be "very advanced."

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

Topics

UsernamePublicRestriction

Register

MT069319

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel